Frank G. A. Jansman
Groningen University Institute for Drug Exploration
Department of Pharmacotherapy & Pharmaceutical Care
University of Groningen
Groningen
Netherlands
Name/email consistency: high
- Cost considerations in the treatment of colorectal cancer. Jansman, F.G., Postma, M.J., Brouwers, J.R. Pharmacoeconomics (2007)
- Fatal anaphylactoid reaction following ioversol administration. Jansman, F.G., Kieft, H., Harting, J.W. Pharm. World. Sci (2007)
- Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Jansman, F.G., Idzinga, F.S., Smit, W.M., de Graaf, J.C., Coenen, J.L., Sleijfer, D.T., Brouwers, J.R. Clin. Ther (2005)
- Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Jansman, F.G., Postma, M.J., van Hartskamp, D., Willemse, P.H., Brouwers, J.R. Clin. Ther (2004)
- Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Jansman, F.G., Coenen, J.L., De Graaf, J.C., Tobi, H., Sleijfer, D.T., Brouwers, J.R. Anticancer Res. (2002)
- Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Jansman, F.G., Sleijfer, D.T., de Graaf, J.C., Coenen, J.L., Brouwers, J.R. Drug. Saf (2001)
- Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Jansman, F.G., Sleijfer, D.T., Coenen, J.L., De Graaf, J.C., Brouwers, J.R. Drug. Saf (2000)
